drugset / Trial / NCT02677207
The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive
Phase 2
Completed
80 enrolled
Tangent Data
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on psychometric performance and residual depressive symptoms in patients who have been diagnosed with unipolar and bipolar depression but currently DO NOT meet criteria for an episode of Major Depression or Manic Episode.
Timeline
- Start
- 2016-02
- Primary completion
- 2017-05
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-39393406 | Small molecule | 200 mg | — |